Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid Biopsy.
Parsortix system
circulating tumor cells
colorectal cancer
cyclooxygenase 2-regulated genes
inflammation-related genes
liquid biopsy
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
10
2021
accepted:
21
12
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Cyclooxygenase 2 (COX2) has been implicated in cancer development and metastasis. We have identified several COX2-regulated inflammation-related genes in human colorectal cancer cells and shown that some of them play important roles in tumor progression. In this work, we have studied the COX2-regulated genes in the mouse colorectal cancer cell line CT26, to find that many are also regulated by COX2 over-expression. On the other hand, we generated a CT26 cell line expressing Gfp and Luciferase, to study tumor growth and metastasis in immunocompetent Balb/c mice. We then collected solid tissue, and blood samples, from healthy and tumor-bearing mice. Using the Parsortix
Identifiants
pubmed: 35153760
doi: 10.3389/fphar.2021.806395
pii: 806395
pmc: PMC8831911
doi:
Types de publication
Journal Article
Langues
eng
Pagination
806395Informations de copyright
Copyright © 2022 Stamatakis, Torres-Gérica, Jiménez-Segovia, Ramos-Muñoz, Crespo-Toro, Fuentes, Toribio, Callejas-Hernández, Carrato, García Bermejo and Fresno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cells. 2019 Aug 13;8(8):
pubmed: 31412616
Oncologist. 2012;17(7):947-55
pubmed: 22643538
Lancet. 2011 Jan 1;377(9759):31-41
pubmed: 21144578
Neoplasia. 2019 Nov;21(11):1073-1084
pubmed: 31734628
Cancer Metastasis Rev. 2011 Dec;30(3-4):363-85
pubmed: 22134655
Front Pharmacol. 2020 Apr 29;11:533
pubmed: 32410997
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
Br J Surg. 2021 Mar 12;108(2):e81-e82
pubmed: 33711133
Am J Gastroenterol. 2021 Feb 1;116(2):433-434
pubmed: 33038127
Diagnostics (Basel). 2018 Apr 28;8(2):
pubmed: 29710776
Oncotarget. 2017 Nov 28;9(1):812-823
pubmed: 29416657
J Cell Mol Med. 2019 May;23(5):3603-3615
pubmed: 30887697
Clin Epigenetics. 2015 Jul 24;7:74
pubmed: 26207152
Expert Opin Ther Targets. 2009 Feb;13(2):209-18
pubmed: 19236238
Cancer Res. 2003 Apr 1;63(7):1568-75
pubmed: 12670906
Oncol Rep. 2011 Jun;25(6):1669-703
pubmed: 21455578
J Vis Exp. 2007;(10):484
pubmed: 18989400
Oncotarget. 2015 Nov 24;6(37):39941-59
pubmed: 26498686
Cancer Biol Ther. 2014 May;15(5):496-503
pubmed: 24521660
Mol Ther. 2013 Jan;21(1):119-30
pubmed: 22760540
Oncogene. 2010 Feb 11;29(6):781-8
pubmed: 19946329
Lancet. 2012 Apr 28;379(9826):1591-601
pubmed: 22440947
Ann Oncol. 2015 Mar;26(3):535-41
pubmed: 25515656
Cancers (Basel). 2019 Nov 09;11(11):
pubmed: 31717606
J Cell Biochem. 2019 Apr;120(4):4935-4941
pubmed: 30260024
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:187-96
pubmed: 12432918
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645